Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 352 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sham Injection Procedure Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

NCT04432831
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab, Sham Procedure
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
119
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 28, 2026, 6:19 PM EDT
Withdrawn Not applicable Interventional

Transversus Abdominis Plane (TAP) Block After Kidney Transplantation

NCT01496729
View directory record Official record
Conditions
Transplantation, Kidney
Interventions
Transversus abdominis plane (TAP) block, Sham TAP block with normal saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 28, 2026, 6:19 PM EDT
Recruiting Not applicable Interventional

Erector Spinae Plane Block for Acute Back Pain in the Emergency Department

NCT06745453
View directory record Official record
Conditions
Low Back Pain
Interventions
Erector Spinae Plane Block, Sham Procedure
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 28, 2026, 6:19 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

NCT00358423
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib Sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Oct 28, 2026, 6:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

PRINT Trial (Platelet Rich Injection vs Needle Tenotomy)

NCT03504111
View directory record Official record
Conditions
Lateral Epicondylitis, Tendinosis, Elbow, Tennis, Elbows Tendonitis
Interventions
Percutaneous Needle Tenotomy, PRP
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 28, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

NCT04200248
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
RBM-007 Injectable Solution, Aflibercept, Sham
Drug
Lead sponsor
Ribomic USA Inc
Industry
Eligibility
55 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 28, 2026, 6:19 PM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)

NCT06178055
View directory record Official record
Conditions
Central Retinal Artery Occlusion
Interventions
KUS121 high dose, KUS121 low dose, Sham procedure
Drug
Lead sponsor
Kyoto Drug Discovery and Development Co., Ltd.
Industry
Eligibility
20 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
Encino, California • Huntington Beach, California • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 28, 2026, 6:19 PM EDT
Terminated Phase 4 Interventional

Validity and Reliability of Diagnostic Findings of SI Joint Blocking

NCT01874236
View directory record Official record
Conditions
SI Joint Pain
Interventions
0.75% bupivacaine, .75% bupivacaine
Drug
Lead sponsor
SI-BONE, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Mount Vernon, Illinois • Lexington, Kentucky • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 28, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of NGM621 in Participants With Geographic Atrophy

NCT04465955
View directory record Official record
Conditions
Geographic Atrophy
Interventions
NGM621, Sham Comparator
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
55 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
65
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 28, 2026, 6:19 PM EDT
Recruiting Phase 4 Interventional

Concentrated Bone Marrow Aspirate in Revision ACL Reconstruction

NCT06311513
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Post-Traumatic Osteoarthritis of Knee, Bone Marrow Aspirate Concentrate, ACL Injury
Interventions
Concentrated Bone Marrow Aspirate Injection, Sham Incision, Revision Anterior Cruciate Ligament Reconstruction
Biological · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 28, 2026, 6:19 PM EDT
Not yet recruiting Not applicable Interventional

Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy

NCT07483320
View directory record Official record
Conditions
Achilles Injuries Tendon, Achilles Tendinopathy (AT), Achilles Tendinitis, Left Leg, Achilles Tendinitis, Right Leg, Achilles Tendon Pain, Achilles Tendonitis
Interventions
Platelet Rich Plasma, Extracorporeal Shockwave Therapy, Sham PRP, Sham ESWT
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 6:19 PM EDT
Terminated Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04611152
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
La Jolla, California • Redlands, California • Santa Maria, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 28, 2026, 6:19 PM EDT
Completed Not applicable Interventional Results available

Randomized Evaluation of the Efficacy of Synvisc-One® for the Treatment of Patellofemoral Chondromalacia

NCT01771952
View directory record Official record
Conditions
Chondromalacia Patella, Patellofemoral Pain Syndrome
Interventions
Synvisc-One™, Sham Treatment
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
15 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 28, 2026, 6:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Intercostobrachial Nerve Block's Effect on Pain Control After Shoulder Replacement

NCT06042608
View directory record Official record
Conditions
Postoperative Pain, Acute, Shoulder Pain
Interventions
intercostobrachial nerve block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 28, 2026, 6:19 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

NCT06627179
View directory record Official record
Conditions
Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
8 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 28, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Body and Social Behavior

NCT05654441
View directory record Official record
Conditions
Psychology, Social, Inflammation, Defeat, Social, Interaction, Social
Interventions
Influenza vaccine, Placebo
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 28, 2026, 6:19 PM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

NCT07832552
View directory record Official record
Conditions
Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions
Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
Procedure · Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 28, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

NCT03607838
View directory record Official record
Conditions
Lumbar Disc Herniation
Interventions
SI-6603, Sham injection
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
30 Years to 70 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
67
States / cities
Mobile, Alabama • Fountain Valley, California • La Jolla, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 28, 2026, 6:19 PM EDT
Terminated Phase 1 Interventional

Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity

NCT01810848
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Hylan G-F 20, Control
Device · Other
Lead sponsor
OhioHealth
Other
Eligibility
40 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 28, 2026, 6:19 PM EDT
Recruiting Not applicable Interventional

Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries

NCT03517761
View directory record Official record
Conditions
Craniocervical Injuries
Interventions
Bone Marrow Concentrate treatment, Sham Control
Biological · Other
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 28, 2026, 6:19 PM EDT
Not listed Not applicable Interventional

Erector Spinae Plane Block for Minimally Invasive Mitral Valve Surgery

NCT04770961
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Valve Insufficiency, Mitral Valve Prolapse
Interventions
Erector spinae plane catheter with 0.5% Ropivacaine, Erector spinae plane catheter with saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 28, 2026, 6:19 PM EDT
Not yet recruiting Phase 4 Interventional

A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery

NCT07570940
View directory record Official record
Conditions
Coronary Artery Disease, Atrial Fibrillation
Interventions
Liposomal bupivacaine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 6:19 PM EDT
Completed Phase 3 Interventional

A Study of SI-6603 in Patients With Lumbar Disc Herniation

NCT01941563
View directory record Official record
Conditions
Intervertebral Disc Disease, Lumbar Disc Disease
Interventions
Condoliase, placebo
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
30 Years to 70 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • Gold River, California • Laguna Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 28, 2026, 6:19 PM EDT
Completed Phase 3 Interventional

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

NCT03584165
View directory record Official record
Conditions
Choroideremia, X-Linked Retinitis Pigmentosa
Interventions
BIIB111, BIIB112
Genetic
Lead sponsor
NightstaRx Ltd, a Biogen Company
Other
Eligibility
18 Years and older · Male only
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 6:19 PM EDT